EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.


Journal

Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595

Informations de publication

Date de publication:
Nov 2023
Historique:
accepted: 17 08 2023
medline: 23 11 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: ppublish

Résumé

Supplementary file1 (MP4 21169 KB).

Identifiants

pubmed: 37792237
doi: 10.1007/s11523-023-00994-2
pii: 10.1007/s11523-023-00994-2
pmc: PMC10663258
doi:

Substances chimiques

Tyrosine Kinase Inhibitors 0
Protein Kinase Inhibitors 0
ErbB Receptors EC 2.7.10.1
EGFR protein, human EC 2.7.10.1

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

807-817

Subventions

Organisme : NCI NIH HHS
ID : R37 CA218707
Pays : United States

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Value Health. 2018 Nov;21(11):1278-1285
pubmed: 30442274
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
Transl Lung Cancer Res. 2019 Jun;8(3):302-316
pubmed: 31367543
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Front Pharmacol. 2022 Jun 13;13:919652
pubmed: 35770100
Cancer Treat Res Commun. 2022;31:100522
pubmed: 35189530
J Thorac Oncol. 2023 Feb;18(2):169-180
pubmed: 36307041
Front Oncol. 2022 Feb 11;12:843299
pubmed: 35223527
Pathol Oncol Res. 2019 Oct;25(4):1401-1409
pubmed: 30094734
Mol Diagn Ther. 2017 Oct;21(5):555-562
pubmed: 28589341
Int J Mol Sci. 2019 Mar 21;20(6):
pubmed: 30901844
J Thorac Oncol. 2020 May;15(5):803-815
pubmed: 31931137
J Thorac Dis. 2018 Dec;10(12):E802-E805
pubmed: 30746257
JTO Clin Res Rep. 2022 Feb 15;3(3):100291
pubmed: 35295963
Ann Transl Med. 2019 Mar;7(5):80
pubmed: 31019930
JTO Clin Res Rep. 2022 Jan 25;3(3):100285
pubmed: 35199057
Hum Genomics. 2019 Aug 1;13(1):34
pubmed: 31370908
Front Oncol. 2022 Apr 28;12:834704
pubmed: 35574304
Curr Oncol. 2022 Jan 09;29(1):255-266
pubmed: 35049698
Clin Transl Oncol. 2018 Oct;20(10):1261-1267
pubmed: 29623586
Clin Lung Cancer. 2022 Jun;23(4):311-319
pubmed: 35045945
Nature. 2021 Sep;597(7878):732-737
pubmed: 34526717
J Thorac Oncol. 2015 May;10(5):793-799
pubmed: 25668120
Clin Genet. 2018 Mar;93(3):533-544
pubmed: 29265354
J Natl Compr Canc Netw. 2022 May;20(5):497-530
pubmed: 35545176
Transl Lung Cancer Res. 2022 Jun;11(6):953-963
pubmed: 35832438
Lung Cancer. 2020 Dec;150:9-11
pubmed: 33035779
Thorac Cancer. 2018 Jun;9(6):745-749
pubmed: 29673089
Ther Adv Med Oncol. 2020 Aug 10;12:1758835920946156
pubmed: 32843903
J Clin Oncol. 2020 Feb 10;38(5):488-495
pubmed: 31825714

Auteurs

Xiuning Le (X)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xle1@mdanderson.org.

Eric Nadler (E)

Baylor University Medical Center, Dallas, TX, USA.

Daniel B Costa (DB)

Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

John Victor Heymach (JV)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH